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Abstract
Background: RET/PTC rearrangements are the most frequent molecular changes in papillary thyroid carcinoma
(PTC). So far, 15 main RET/PTC rearrangements have been described, among which RET/PTC1 and RET/PTC3 are the
most common in PTC - especially in radiation-induced tumours. RET/PTC1 and RET/PTC3 are the result of
intrachromosomal paracentric inversions in chromosome 10, where RET and the activating genes (H4 and ELE1,
respectively) are located. Recently, RET/PTC rearrangements have been shown not only in PTC but also in benign
thyroid lesions, including Hashimoto’s thyroiditis (HT). The aim of study was an assessment of RET/PTC1 and RET/
PTC3 rearrangements in patients with Hashimoto’s thyroiditis.
Materials and methods: Thyroid aspirates, eligible for the study, were obtained from 26 patients with Hashimoto’s
thyroiditis by fine-needle aspiration biopsy (FNAB). Each aspirate was smeared for conventional cytology, while its
remaining part was immediately washed out of the needle. The cells, obtained from the needle, were used in
further investigation. Total RNA from FNAB was extracted by use of an RNeasy Micro Kit, based on modified
Chomczynski and Sacchi’s method and reverse transcription (RT-PCR) was done. Quantitative evaluation of RET/
PTC1 and RET/PTC3 rearrangements by real-time PCR was performed by an ABI PRISM
® 7500 Sequence Detection
System. In the study, PTC tissues with known RET/PTC1 and RET/PTC3 rearrangements served as a reference
standard (calibrator), while b-actin gene was used as endogenous control.
Results: Amplification reactions were done in triplicate for each examined sample. No RET/PTC1 and RET/PTC3
rearrangements were found in the examined samples.
Conclusions: Our results indicate that RET/PTC1 and RET/PTC3 rearrangements in Hashimoto’s thyroiditis, if any, are
rather rare events and further investigations should be conducted in order to determine molecular changes,
connecting Hashimoto’s thyroiditis with PTC.
Background
Chromosomal rearrangements involving RET receptor
tyrosine kinase (TK) protooncogene (RET/PTC)a r ea
specific feature of papillary thyroid carcinoma (PTC).
The RET protooncogene is activated by fusion of
3’-terminal portion of RET, coding for TK domain, with
the 5’ terminal region of different unrelated genes, lead-
ing to constitutive activation of the RET TK [1]. There
are - at least -15 different RET/PTC rearrangements [2],
but the two: RET/PTC1 and RET/PTC3 are the most
common ones [3]. RET/PTC1 is formed by fusion with
the H4 gene [1], and RET/PTC3 by fusion with the
ELE1 (also designed NCOA4, RFG or ARA70)g e n e[ 4 ] .
However, apart from RET/PTC1 and RET/PTC3,a l lt h e
other variants of rearrangements do not seem to have
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have been isolated just in rare cases [5].
Chromosomal rearrangements of RET in PTC were
found with different frequency, depending on geo-
graphic variability and studied population. The reported
frequency of RET/PTC in PTC varies from 0 to 87% [6].
It is interesting that the frequency of RET/PTC rearran-
gements not only depends on geographical region but
also on applied technique of identification [6].
The relatively high prevalence of RET/PTC rearrange-
ments was described in tumours associated with radiation
exposure [7]. The higher prevalence of RET/PTC3 activa-
tion in PTC was observed in the contaminated areas after
Chernobyl explosion [7]. The analysis of PTC, which
developed after a long latency period after explosion
showed higher prevalence of RET/PTC1 rearrangements
[8]. This can suggest that RET/PTC3 rearrangements may
be typical for radiation-induced childhood PTC with a
short latency period, while RET/PTC1 rearrangements
may be a marker for later-occurring PTC of radiation-
exposed children and adults [8]. RET/PTC rearrangements
have not been found in follicular thyroid carcinomas and
anaplastic thyroid carcinomas [9].
Recently, RET/PTC rearrangements have been shown
not only in PTC but also in Hürthle thyroid adenomas
and carcinomas and also in Hashimoto’s thyroiditis
(HT) [10,11].
The prevalence of RET/PTC rearrangements in HT is
still controversial. The study aimed at estimating the fre-
quency of rearrangements of RET protooncogene in HT
in the Polish population.
Materials and methods
The Ethical Committee of the Medical University of
Lodz approved the studies in this paper.
Patients
Thyroid aspirates, eligible for this study, were obtained
from patients undergoing FNAB for Hashimoto’s thyroi-
ditis. All tissue samples were taken after patients’
informed consent was obtained. FNAB specimens from
26 patients (25 women, 1 man) were examined. Data
characterising the patients involved in the study are pre-
sented in Table 1. The mean age of patients was 52.8 ±
15.4 years (mean ± SD), ranging from 18 to 88 years.
Thyroiditis was diagnosed, according to clinical symp-
toms and signs, together with data of hormonal and
immunological tests and the results of cytological eva-
luation of FNAB specimens, collected under ultrasound
guidance.
Ultrasound-guided FNAB was performed with the use
of a 22-gauge needle and each aspirate was smeared for
conventional cytology, while the remaining material was
immediately washed out of the needle with 350 μlo f
RLT lysis buffer, containing b-mercaptoethanol and gua-
nidine thiocyanate, used for RNA isolation (Qiagen,
Germany). The samples were immediately frozen at
-70°C and, thus, stored until total RNA isolation. The
samples, containing visible blood contamination, were
disqualified from further investigations.
RNA extraction from FNAB
Total RNA from FNAB was extracted with the use of
RNeasy Micro Kit (Qiagen, Germany). The manufacturer’s
instructions were followed, except that the cell lysate was
applied for the second time to the column before the
wash-step was carried out. The quality and quantity of
total RNA was spectrophotometrically measured and - for
some samples - with an Agilent 2100 Bioanalyzer.
Reverse transcription
Reverse transcription (RT) was performed, using the
whole RNA, extracted with TaqMan
® Reverse Tran-
scripton Reagents (Applied Biosystems, Branchburg,
Table 1 Characteristics of HT patients involved in the
study
Case number Sex Age Diagnosis
1 F 68 HT
2 F 67 HT
3 F 48 HT
4 F 45 HT
5 F 37 HT
6 F 68 HT
7 F 18 HT
8 F 53 HT
9 F 31 HT
10 F 52 HT
11 F 63 HT
12 F 54 HT
13 F 83 HT
14 F 88 HT
15 F 39 HT
16 F 50 HT
17 F 51 HT
18 F 41 HT
19 F 41 HT
20 F 49 HT
21 F 38 HT
22 F 65 HT
23 F 51 HT
24 F 54 HT
25 F 63 HT
26 M 57 HT
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of 10 × TaqMan RT Buffer (100 mM Tris-HCl pH 8.3,
500 mM KCl), 11.0 μl2 5m MM g C l 2,1 . 2 5μlM u l t i
Scribe™ reverse transcriptase (50 U/μl), 2.5 μl5 0μM
oligo(dT)16,1 . 0μl RNase Inhibitor - RI (20 U/μl), and
10 μl 10 mM dNTPs in a total volume of 50 μl. RNAs
were incubated for 10 minutes at 25°C, followed by
30 minutes at 48°C and 5 minutes at 95°C to inactivate
reverse transcriptase (Multi Scribe™). Negative controls
were performed simultaneously to eliminate a possible
genomic DNA contamination (no reverse transcriptase
reactions), as well as to eliminate a possible contamina-
tion of RT reagents (no RNA-added reactions).
Real-time quantitative PCR
An established Relative Quantification Polymerase Chain
Reaction (RQ-PCR) assay for RET/PTC1 and RET/PTC3
mRNA expressions, using the relative quantification
method (ΔΔCT) were conducted in ABI PRISM 7500
Sequence Detection System (Applied Biosystems),
according to the manufacturer’sp r o t o c o l .T h eP C R
reactions for RET/PTC1 and RET/PTC3 rearrangements
of genes were run with 50 ng of cDNA in a total volume
of 50 μl, using TaqMan
® Universal PCR Master Mix
(Applied Biosystems, Foster City, CA, USA) and the pre-
designed and labelled primer/probe set (Applied Biosys-
tems, Foster City, CA, USA). Sequences of primers and
probes used for this study were reported and validated
according to Rhoden’s et al. protocol (Table 2) [12].
After initial incubation at 50°C for 2 min to allow ura-
cil-N-glycosylase (UNG) digestion, and at 95°C for 10
min to activate the AmpliTaq Gold
®DNA polymerase,
both of them were provided by the Universal PCR Mas-
ter Mix, the samples were amplified through 45 biphasic
cycles of 95°C for 15 sec and 60°C for 1 min (Table 3).
In the study, PTC tissues with known RET/PTC1 and
RET/PTC3 rearrangements served as a reference stan-
dard (calibrator) [13]. Amplification reactions were done
in triplicate for each sample (cDNA from the same PCR
reaction but in separate wells). Controls with no tem-
plate cDNA were used with each assay (negative
control).
The expression levels of b-actin gene (ACTB)w e r e
measured, as endogenous control (reference gene), using
the appropriate Assays-on-Demand™ Gene Expression
product (Hs99999903_ml, Applied Biosystems Foster
City, CA, USA).
Both gene expressions were measured for each thyroid
lesion sample in the same PCR reaction but in separate
wells.
Results were presented as Rn (normalized receptor)
versus cycle graph, where Rn is the fluorescence of the
receptor dye, divided by fluorescence of a passive refer-
ence dye (Figure 1 and 2).
Results
The specimens were amplified in the ABI PRISM 7500
Sequence Detection System in reaction, containing primers
and probes for RET/PTC1 and RET/PTC3 rearrangements
and a control gene, b-actin. The Sequence Detection Sys-
tem software, provided with the instrument, analyses the
fluorescence data, generated during the reaction, and calcu-
lates the cycle number at which fluorescence crosses the
threshold value (CT). Amplification reactions were done in
triplicate for each examined sample.
No RET/PTC1 and RET/PTC3 rearrangements were
found in the examined HT specimens (for RET/PTC1 -
see Figure 1 and 2; for RET/PTC3 - data not shown).
Discussion
T h ep r e v a l e n c eo fRET/PTC rearrangements in Hashi-
moto’s thyroiditis remains a subject of controversy.
Some authors have described activation of RET protoon-
c o g e n ei nt h em a j o r i t yn u m b e ro fH Tp a t i e n t s .S h e i l s
et al. [14] have shown the presence of RET/PTC1 rear-
rangement in a significant number of HT cases (95%).
The majority of specimens have shown no evidence of
concomitant PTC [14]. Wirtschafter et al.a l s oh a v e
documented the presence of transcripts of RET/PTC1
and RET/PTC3 in 95% cases of HT [15]. Their study
has suggested that multiple, independent occult PTCs
exist in patients with HT at high frequency and RET/
PTC1 and RET/PTC3 are early molecular markers of
Table 2 The sequences of probes and primers of RET/PTC1 and RET/PTC3 gene rearrangements [12]
Gene Amplicon (bp) Forward primer Reverse primer Probe sequence
RET/PTC1 66 CGCGACCTGCGCAAA CAAGTTCTTCCGAGGGAATTCC 6FAM-CAAGCGTAACCATCGAGGATCCAAAGT-TAMRA
RET/PTC3 81 CCCCAGGACTGGCTTACCC CAAGTTCTTCCGAGGGAATTCC 6FAM-AAAGCAGACCTTGGAGAACAGTCAGGAGG-TAMRA
Table 3 Amplification conditions for RET/PTC1 and RET/
PTC3 rearrangements using real-time PCR
Times and temperatures
Each of 45 cycles
Initial setup Denaturation Annealing/
Elongation
HOLD HOLD CYCLE
UNG activation 2 min,
50°C
10 min,
95°C
15 s, 95°C 1 min, 60°C
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technical limitations, the authors used highly degraded
RNA which was isolated from formalin-fixed and paraf-
fin-embedded tissues. Kang et al. [16] have investigated
the expression of RET, RAS and ERK proteins in oxy-
philic cells in HT. They have shown greatly enhanced
immunoexpression of these proteins, suggesting a mole-
cular link between oxyphilic cell metaplasia in HT and
the progression of PTC [16].
Rhoden et al. [11] have analyzed RET/PTC oncogenic
activation in HT, PTC, oncocytic tumours and in nor-
mal thyroid samples using three independent techni-
ques: real-time RT-PCR, laser capture microdissection
(LCM) RT-PCR, and fluorescence in situ hybridization
(FISH) method. In their study, normal samples have not
shown RET protooncogene rearrangement. Sixty eight
percent of HT were positive by FISH analysis, whereas
only 17% HT have shown RET/PTC activation by real-
time PCR. It is interesting that these conflicting results
depended only on the method used in the study [11].
Despite some technical controversies (RT-PCR should
be typically more sensitive method of detection than
FISH), the importance of this paper is expressed
through providing additional evidence for the possibility
of presence RET/PTC rearrangements in a subpopula-
tion of cells within the thyroid gland affected by HT.
On the other hand, other groups have not detected
RET rearrangements in histologically benign thyroid tis-
sue with HT. Moreover, they have not shown RET/PTC
activation in PTCs arising on the background of HT, in
contrast to PTC not associated with that disease [17].
Also, Sadow et al. have not identified RET/PTC1 and
RET/PTC3 in dominant nodules from Hashimoto’sg o i -
tre, supporting the notion that these nodules are neither
malignant nor precursor lesions of PTC [18].
In our study, we have performed real-time relative
PCR assay for RET/PTC1 and RET/PTC3 rearrange-
ments, based on fluorescent TaqMan methodology and
using the ABI PRISM 7500 Sequence Detection System
(Applied Biosystems). Real-time PCR is a sensitive, pre-
cise technique for detection of nucleic acids. Unfortu-
n a t e l y ,w eh a v en o tf o u n dRET/PTC1 and RET/PTC3
rearrangements in the examined samples of patients
w i t hH T .O no n eh a n d ,i tc o u l db ear e s u l to ft h el i m -
ited number of cases of HT in our study, on the other,
Figure 1 Representative amplification curves for b-actin gene
(curve no. 1) and RET/PTC1 rearrangement (curves nos. 2a, 2b,
2c) in PTC specimen.
Figure 2 Representative amplification curves for b-actin gene
(curves nos. 1a, 1b) and RET/PTC1 rearrangement (curves nos.
2a, 2b, 2c) in HT specimen.
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to’s thyroiditis and follicular cell-derived thyroid
tumours, as well as RET/PTC rearrangements as a puta-
tive link between them, remain still controversial.
In summary, the results of our study indicate that
RET/PTC1 and RET/PTC3 rearrangements in Hashimo-
to’s thyroiditis, if any, are rather rare events and further
investigations seem to be necessary to determine mole-
cular changes associating Hashimoto’s thyroiditis with
PTC.
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